Hoth Therapeutics, Inc. Terminates Use of ATM Prospectus Supplement

Key Highlights from the April 16, 2026, SEC 8-K Filing

• Company: Hoth Therapeutics, Inc. (NASDAQ: HOTH)
• Event: Termination of Prospectus Supplement for At-The-Market (ATM) Sales Agreement
• Date of Report: April 16, 2026
• Relevant Agreement: At-The-Market Offering Agreement with H.C. Wainwright & Co., LLC, originally dated November 8, 2024

Detailed Article

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker HOTH, has announced an important update regarding its capital markets activities. On April 16, 2026, the company filed an 8-K with the U.S. Securities and Exchange Commission (SEC) highlighting the suspension and termination of its use of the prospectus supplement and related prospectus that allowed for the potential issuance of its common stock through an “At-The-Market” (ATM) Offering Agreement.

What Has Changed?

The company has officially suspended and terminated the use of its prospectus supplement and related prospectus for the ATM Sales Agreement with H.C. Wainwright & Co., LLC. This means Hoth will no longer be issuing shares under this specific ATM program, which had previously enabled the company to raise funds flexibly by selling shares directly into the open market from time to time.

The underlying Sales Agreement itself remains in place, but the prospectus relating to it is no longer effective, as previously filed and declared effective by the SEC on December 4, 2025.

Why Is This Significant?

• Capital Raising Impact: The ATM program had provided Hoth with the ability to raise capital efficiently. Its termination may signal a change in the company’s financing strategy, a reassessment of capital needs, or management’s view on the current share price and market conditions.
• Potential Share Price Sensitivity: The suspension of ATM offerings could be perceived positively by shareholders concerned about dilution, as no further shares will be issued under this mechanism for now. Conversely, it may also prompt questions about the company’s future funding plans.
• Legal Proceedings: The company included the legal opinion and consent of Sheppard, Mullin, Richter & Hampton LLP regarding the validity of the securities under the Sales Agreement as part of the filing, reaffirming the legal compliance of previous ATM-related activities.

What Should Investors Watch For?

• Future Capital Raises: Investors should monitor future announcements from Hoth regarding alternative fundraising approaches, as the termination of the ATM prospectus supplement does not necessarily mean that the company will not seek other equity or debt financings.
• Strategic Shifts: The move may indicate a shift in strategic direction or operational priorities. Watch for updates on cash runway, R&D progress, or potential partnerships.
• Share Dilution: The immediate risk of dilution from this ATM vehicle is off the table, which could reduce share supply concerns in the short term.

Other Administrative Details

• Trading Details: Hoth Therapeutics’ common stock (\$0.0001 par value) is listed on NASDAQ under the symbol “HOTH”.
• Emerging Growth Company: Hoth remains classified as an emerging growth company, which can have implications for financial reporting and compliance obligations.
• No Other Events Disclosed: The filing did not indicate any other material, price-sensitive corporate events or changes.

Potential Share Price Impact

The termination of the ATM prospectus supplement is a noteworthy development for current and prospective shareholders. The market may interpret the decision as a signal of management’s confidence in the company’s current financial standing, or conversely, as a sign that alternative fundraising is being considered. The impact on HOTH’s share price will depend on investor sentiment regarding dilution risk, capital needs, and the company’s strategic outlook.

Next Steps

Investors are encouraged to remain attentive to future SEC filings, press releases, and company communications addressing Hoth’s financial position, upcoming milestones, or any new capital market activities.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The information above is based on the company’s public SEC filings as of April 16, 2026.

View Hoth Therapeutics, Inc. Historical chart here